Influence	O
of	O
drug	B:C1254351
load	O
on	O
dissolution	O
behavior	O
of	O
tablets	O
containing	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
:	O
estimation	O
of	O
the	O
percolation	O
threshold	O
.	O

Influence	O
of	O
drug	O
load	O
on	O
dissolution	O
behavior	O
of	O
tablets	B:C0039225
containing	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
:	O
estimation	O
of	O
the	O
percolation	O
threshold	O
.	O

Influence	O
of	O
drug	O
load	O
on	O
dissolution	O
behavior	O
of	O
tablets	O
containing	O
a	O
poorly	O
water	B:C0043047
-	O
soluble	O
drug	O
:	O
estimation	O
of	O
the	O
percolation	O
threshold	O
.	O

Influence	O
of	O
drug	O
load	O
on	O
dissolution	O
behavior	O
of	O
tablets	O
containing	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	B:C1254351
:	O
estimation	O
of	O
the	O
percolation	O
threshold	O
.	O

Drug	B:C1254351
load	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
solid	O
dosage	I:C1378566
forms	I:C1378566
,	O
since	O
it	O
can	O
significantly	O
influence	O
both	O
processability	O
and	O
final	O
product	O
properties	O
.	O

Drug	O
load	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
solid	B:C1378566
dosage	I:C1378566
forms	I:C1378566
,	O
since	O
it	O
can	O
significantly	O
influence	O
both	O
processability	O
and	O
final	O
product	O
properties	O
.	O

The	O
percolation	O
threshold	O
of	O
the	O
active	B:C1372955
pharmaceutical	I:C1372955
ingredient	I:C1372955
(	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
)	O
corresponds	O
to	O
a	O
critical	O
concentration	O
,	O
above	O
which	O
an	O
abrupt	O
change	O
in	O
drug	O
product	O
characteristics	O
can	O
occur	O
.	O

The	O
percolation	O
threshold	O
of	O
the	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
(	O
active	B:C1372955
pharmaceutical	I:C1372955
ingredient	I:C1372955
)	O
corresponds	O
to	O
a	O
critical	O
concentration	O
,	O
above	O
which	O
an	O
abrupt	O
change	O
in	O
drug	O
product	O
characteristics	O
can	O
occur	O
.	O

The	O
percolation	O
threshold	O
of	O
the	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
(	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
)	O
corresponds	O
to	O
a	O
critical	O
concentration	O
,	O
above	O
which	O
an	O
abrupt	O
change	O
in	O
drug	B:C1254351
product	O
characteristics	O
can	O
occur	O
.	O

The	O
objective	B:C0018017
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	O
.	O

The	O
objective	O
of	O
this	O
study	B:C2603343
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	B:C0043047
-	O
soluble	O
drug	O
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	B:C1254351
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
percolation	O
threshold	O
of	O
a	O
poorly	O
water	O
-	O
soluble	O
drug	O
with	O
regard	O
to	O
the	O
dissolution	O
behavior	O
from	O
immediate	O
release	O
tablets	B:C0039225
.	O

The	O
influence	O
of	O
the	O
active	B:C1372955
pharmaceutical	I:C1372955
ingredient	I:C1372955
particle	O
size	O
on	O
the	O
percolation	O
threshold	O
was	O
also	O
studied	O
.	O

Formulations	B:C0524527
with	O
increasing	O
drug	O
loads	O
were	O
manufactured	O
via	O
roll	O
compaction	I:C3830384
using	O
constant	O
process	O
parameters	O
and	O
subsequent	O
tableting	O
.	O

Formulations	O
with	O
increasing	O
drug	B:C1254351
loads	O
were	O
manufactured	O
via	O
roll	O
compaction	I:C3830384
using	O
constant	O
process	O
parameters	O
and	O
subsequent	O
tableting	O
.	O

Formulations	O
with	O
increasing	O
drug	O
loads	O
were	O
manufactured	O
via	O
roll	B:C3830384
compaction	I:C3830384
using	O
constant	O
process	O
parameters	O
and	O
subsequent	O
tableting	O
.	O

Formulations	O
with	O
increasing	O
drug	O
loads	O
were	O
manufactured	O
via	O
roll	O
compaction	I:C3830384
using	O
constant	O
process	O
parameters	O
and	O
subsequent	O
tableting	B:C0039225
.	O

The	O
percolation	O
threshold	O
was	O
estimated	O
via	O
a	O
model	O
dependent	O
and	O
a	O
model	O
independent	O
method	B:C0871511
based	O
on	O
the	O
dissolution	O
data	O
.	O

The	O
intragranular	O
concentration	O
of	O
mefenamic	B:C0025152
acid	I:C0025152
had	O
a	O
significant	O
effect	O
on	O
granules	O
and	O
tablet	O
characteristics	O
,	O
such	O
as	O
particle	O
size	O
distribution	O
,	O
compactibility	O
and	O
tablet	O
disintegration	I:C0991504
.	O

The	O
intragranular	O
concentration	O
of	O
mefenamic	O
acid	I:C0025152
had	O
a	O
significant	O
effect	O
on	O
granules	B:C3853573
and	O
tablet	O
characteristics	O
,	O
such	O
as	O
particle	O
size	O
distribution	O
,	O
compactibility	O
and	O
tablet	O
disintegration	I:C0991504
.	O

The	O
intragranular	O
concentration	O
of	O
mefenamic	O
acid	I:C0025152
had	O
a	O
significant	O
effect	O
on	O
granules	O
and	O
tablet	B:C0039225
characteristics	O
,	O
such	O
as	O
particle	O
size	O
distribution	O
,	O
compactibility	O
and	O
tablet	O
disintegration	I:C0991504
.	O

The	O
intragranular	O
concentration	O
of	O
mefenamic	O
acid	I:C0025152
had	O
a	O
significant	O
effect	O
on	O
granules	O
and	O
tablet	O
characteristics	O
,	O
such	O
as	O
particle	O
size	O
distribution	O
,	O
compactibility	O
and	O
tablet	B:C0991504
disintegration	I:C0991504
.	O

Increasing	O
the	O
intragranular	O
drug	O
concentration	O
of	O
the	O
tablets	B:C0039225
resulted	O
in	O
lower	O
dissolution	O
rates	O
.	O

A	O
percolation	O
threshold	O
of	O
approximately	O
20	O
%	O
v/v	O
could	O
be	O
determined	O
for	O
both	O
particle	O
sizes	O
of	O
the	O
active	B:C1372955
pharmaceutical	I:C1372955
ingredient	I:C1372955
above	O
which	O
an	O
abrupt	O
decrease	O
of	O
the	O
dissolution	O
rate	O
occurred	O
.	O

However	O
,	O
the	O
increasing	O
drug	B:C1254351
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	B:C0039225
containing	O
the	O
micronized	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	B:C3829074
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	O
active	B:C1372955
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	B:C3829074
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	B:C3830384
compaction	I:C3830384
and	O
tableting	O
.	O

However	O
,	O
the	O
increasing	O
drug	O
load	O
had	O
a	O
more	O
pronounced	O
effect	O
on	O
dissolution	O
rate	O
of	O
tablets	O
containing	O
the	O
micronized	O
active	O
pharmaceutical	I:C1372955
ingredient	I:C1372955
,	O
which	O
can	O
be	O
attributed	O
to	O
the	O
high	O
agglomeration	O
tendency	O
of	O
micronized	O
substances	O
during	O
manufacturing	O
steps	O
,	O
such	O
as	O
roll	O
compaction	I:C3830384
and	O
tableting	B:C0039225
.	O

Both	O
methods	B:C0871511
that	O
were	O
applied	O
for	O
the	O
estimation	O
of	O
percolation	O
threshold	O
provided	O
comparable	O
values	O
.	O

